Ten-year survival of women with invasive breast cancer by stage, molecular subtype, and grade combined: a population-based study
The Oncologist · 2026
DOI: 10.1093/oncolo/oyag338 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2026. Verfasst von Fabiola Giudici und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, 33081, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health.
Abstract (Originalsprache)
Background
Stage at diagnosis, histologic grade, and molecular subtypes are established prognostic indicators for women with breast cancer (BC), but their impact on population-based survival estimates is poorly documented. This study assessed long-term BC survival trends according to these factors.
Methods
We identified women aged <75 years diagnosed with stage I-IV invasive BC between 2004 and 2014 from the Friuli Venezia Giulia (north-eastern Italy) Cancer Registry (N = 10 467). Follow-up through 2023 was used to estimate overall and net survival (NS) according to combinations of prognostic factors.
Results
The highest 10-year NS (10-NS) was observed in women with stage I HR+/HER2− subtype (98.8%), while it was 35.1% for stage III triple-negative (TN) subtype. Among women with stage IV BC, 10-NS was 18.9% for those HR−/HER2+, 11.5% for those HR+/HER2+, 8.3% for HR+/HER2−, and 6.7% for TN. For each stage, NS decreased with increasing grade. Comparing periods of diagnosis (2004-2009 vs 2010-2014), 10-NS remained >90% for women with stage I BC, but improved for stage III and aggressive subtypes (HR−/HER2+ and TN). In women with stage III HR−/HER2+ BC, 10-NS increased from 48.6% to 87.9% (+39 percentage points), while when diagnosis was stage III TN BC it rose from 28.8% to 42.3% Conclusion Population-based estimates of long-term BC survival by combined stage, grade, and molecular subtype can inform the interpretation of evolving therapeutic strategies and improve risk stratification for patient follow-up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, 33081, Italy.
- Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, 33081, Italy.
- Department of Medicine, University of Udine, Udine, 33100, Italy.
- Breast Surgery Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, 33081, Italy.
- Breast Surgery Unit, Cattinara University Hospital, Trieste, 34149, Italy.
ORCID-Profile: Fabiola Giudici, Diego Serraino, Fabio Puglisi, Samuele Massarut, Lorenzo Gerratana, Serena Scomersi, Federica Toffolutti, Ettore Bidoli, Luigino Dal Maso
Förderung
- Italian Ministry of Health
Zitieren
APA
Giudici, F., Serraino, D., Puglisi, F., Massarut, S., Gerratana, L., Scomersi, S., Toffolutti, F., Bidoli, E., Dal Maso, L., & Friuli Venezia Giulia Cancer Registry working group (2026). Ten-year survival of women with invasive breast cancer by stage, molecular subtype, and grade combined: a population-based study. The Oncologist. https://doi.org/10.1093/oncolo/oyag338
Vancouver
Giudici F, Serraino D, Puglisi F, Massarut S, Gerratana L, Scomersi S, et al. Ten-year survival of women with invasive breast cancer by stage, molecular subtype, and grade combined: a population-based study. The Oncologist. 2026. doi:10.1093/oncolo/oyag338
BibTeX
@article{Giudici2026,
author = {Giudici, Fabiola and Serraino, Diego and Puglisi, Fabio and Massarut, Samuele and Gerratana, Lorenzo and Scomersi, Serena and Toffolutti, Federica and Bidoli, Ettore and Dal Maso, Luigino and Friuli Venezia Giulia Cancer Registry working group, Friuli Venezia Giulia Cancer Registry working group},
title = {Ten-year survival of women with invasive breast cancer by stage, molecular subtype, and grade combined: a population-based study},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyag338}
}
EUVIMED